The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept

Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept

January 19, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GCA Relapse Possible When Discontinuing Tocilizumab

Image Credit: ajt/shutterstock.com

Image Credit: ajt/shutterstock.com

In a Phase 2 randomized, controlled trial, tocilizumab, an anti-IL-6 biologic agent, was shown to induce and maintain remission for up to 52 weeks in patients with giant cell arteritis (GCA).1 During this trial, patients with GCA were randomized in a 2:1 ratio to receive 8 mg/kg bodyweight tocilizumab intravenously plus glucocorticoids (n=20; prednisolone up to 1 mg/kg bodyweight for a maximum of 10 days trial inclusion and the first infusion); or placebo plus glucocorticoids (n=10; prednisolone up to 1 mg/kg body weight for a maximum of 10 days trial inclusion and the first infusion). Sixteen (80%) and seven (70%) patients, respectively, from the tocilizumab vs. placebo treatment of patients had new-onset GCA.

You Might Also Like
  • Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis
  • Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA
  • Abatacept Plus Prednisone Therapy Studied for Treating Giant Cell Arteritis
Explore This Issue
January 2017
Also By This Author
  • Denosumab vs. Zoledronate: An Analysis of Treatments for Low Bone Mineral Density in Patients with HIV

Patients received either treatment every four weeks for 52 weeks. By Week 12, 17 (85%) tocilizumab-treated patients and four (40%) placebo-treated patients achieved complete remission. Relapse-free survival was realized by 17 (85%) tocilizumab-treated patients and two (20%) placebo-treated patients by Week 52.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

After Week 52, tocilizumab treatment was discontinued, and subsequent therapy was prescribed by physicians while patients were followed clinically.2 This follow-up study subsequently analyzed patient outcomes after the termination of the Phase 2 trial. Median follow-up time was 12.5 months (range: 3–32 months). After the last tocilizumab dose, 11 patients relapsed, in a median time of five months (range: 2–14 months). In the placebo-treated patients, nine patients relapsed and/or continued glucocorticoid treatment. Interestingly, one of the placebo-treated patients maintained remission throughout the study and was without medication at last follow-up appointment—10 months after Phase 2 study completion.

Of the patients who relapsed, none had blindness, aortic rupture, aortic stenosis or other major vascular complications. Additionally, six of the 11 tocilizumab-treated patients who relapsed after the last study infusion were readministered tocilizumab at the same dose and given monthly intravenous infusions after a median time of 6.5 months (range: 3–14). In two of these tocilizumab-treated patients when the drug was reintroduced, it was stopped after four and six months, with lasting remission. In one of these patients, tocilizumab was reintroduced for two months, stopped and then restarted six months later due to a second relapse.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The authors conclude that clinical and serologic remission in response to monthly, intravenous tocilizumab for 52 weeks does not result in relapse-free survival after treatment termination. Although IL-6 blockade controls the clinical disease, it may not control pathogenesis in all cases and, therefore, requires further study.

Clinical & serologic remission in response to monthly, intravenous tocilizumab for 52 weeks does not result in relapse-free survival after treatment termination. Although IL-6 blockade controls the clinical disease, it may not control pathogenesis in all cases.

FDA Update on Rituximab & Etanercept

The U.S. Food and Drug Administration (FDA) is currently considering an application for a subcutaneous formulation of rituximab. The agency has also approved a supplemental application for etanercept to treat pediatric patients with plaque psoriasis.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Approval, drug, etanercept, FDA, Giant Cell Arteritis, outcome, patient care, Quality, relapse, Research, rheumatology, rituximab, Safety, trialIssue: January 2017

You Might Also Like:
  • Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis
  • Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA
  • Abatacept Plus Prednisone Therapy Studied for Treating Giant Cell Arteritis
  • Updates on Giant Cell Arteritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)